ANALIZE MEDICALE DE LABORATOR
Aici gasiti analizele medicale grupate pe categorii precum si detalii generale si specifice pentru categoriile respective.
Selectati o categorie din lista de mai jos:
Solutie antistress!
Construieste poduri :)
Prinde pisica neagra :)
Lpath Demonstrates Preclinical Efficacy Of Lpathomab(TM) And Initiates Humanization Process
Lpath, Inc. (OTC Bulletin
Board: LPTN), the category leader in therapeutic agents against bioactive
lipids, reported positive results in several murine models of human cancer
and AMD with Lpathomab(TM), the company's mouse monoclonal antibody against
LPA (lysophosphatidic acid). These results confirm the expected potent
anti angiogenic and anti metastatic actions of Lpathomab. Lpathomab was
created using Lpath's proprietary ImmuneY2(TM) platform technology.
Based on this positive outcome, Lpath will collaborate with DataMabs of
London, England, to humanize Lpathomab to create a lead antibody for pre
clinical development.
LPA is a bioactive lipid long recognized as a significant promoter of
cancer cell growth and metastasis in a broad range of tumor types, as well
as a significant contributor to neuropathic pain.
"Humanizing our Lpathomab antibody is a vital next step in moving the
project into the clinic," said Genevieve Hansen, Ph.D., Lpath's vice
president of research. "We've had great success in the past working with
DataMabs and look forward to working with them again on our Lpathomab
project."
This achievement with Lpathomab comes on the heels of Lpath's success
with its Sphingomab(TM) program. Sphingomab is an antibody against another
bioactive lipid, S1P. Lpath humanized the antibody in 2006 and plans to
file an IND in November of this year for the use of ASONEP(TM) (the
systemic formulation of humanized Sphingomab) for the treatment of cancer.
It also plans to file a second IND early next year for the use of
iSONEP(TM) (the ocular formulation of humanized Sphingomab) for the
treatment of AMD. The company plans to submit an IND filing for the use of
humanized Lpathomab in 2009.
Dr. Roger Sabbadini, the founder and CSO of Lpath, commented, "These
exciting results provide further validation of lipidomic-based therapeutics
as an important new area of drug discovery. Lpath was one of the first
companies to recognize that bioactive-lipid-signaling molecules, like S1P
and LPA, could be excellent targets for rational drug design. By pursuing
these targets and demonstrating compelling efficacy, we've opened up an
entire class of lipidomic-based therapeutics for the treatment of cancer,
diabetes, neurodegenerative disorders, immune function, inflammation, pain,
mental disorders, and cardiovascular disease."
Scientists now believe that there are over 1,000 members of the
functional lipidome, each of which is a new potential target for
therapeutic intervention.
About Lpath:
Lpath, Inc., headquartered in San Diego, California, is the category
leader in lipidomics-based therapeutics, an emerging field of medical
science whereby bioactive signaling lipids are targeted for treating
important human diseases. ASONEP(TM) (the systemic formulation of humanized
form of Sphingomab(TM)) is an antibody against S1P that holds promise for
the treatment of cancer and other diseases. A second product candidate,
iSONEP(TM) (the ocular formulation of humanized Sphingomab), has
demonstrated superior results in various preclinical AMD and retinopathy
models. Lpath's third product candidate, Lpathomab(TM), is an antibody
against LPA, a key bioactive lipid that has been long recognized as a valid
disease target. The company's unique ability to generate novel antibodies
against bioactive lipids is based on its ImmuneY2(TM) drug-discovery
engine, which the company is using to add to its pipeline. For more
information, visit http://www.Lpath.com
Forward Looking Statements
Except for statements of historical fact, the matters discussed in this
press release are forward looking and reflect numerous assumptions and
involve a variety of risks and uncertainties, many of which are beyond our
control and may cause actual results to differ materially from stated
expectations. For example, there can be no assurance that required clinical
trials will be successful, necessary regulatory approvals will be obtained,
or the proposed treatments will prove to be safe or effective. Actual
results may also differ substantially from those described in or
contemplated by this press release due to risks and uncertainties that
exist in our operations and business environment, including, without
limitation, our limited experience in the development of therapeutic drugs,
our dependence upon proprietary technology, our history of operating losses
and accumulated deficits, our reliance on research grants, current and
future competition, and other risks described from time to time in our
filings with the Securities and Exchange Commission. We undertake no
obligation to release publicly the results of any revisions to these
forward-looking statements to reflect events or circumstances arising after
the date hereof.
Lpath, Inc.
http://www.lpath.com
Lpath preclinice demonstreazã eficacitatea Lpathomab (TM) ºi iniþiazã umanizarea procesului - Lpath Demonstrates Preclinical Efficacy Of Lpathomab(TM) And Initiates Humanization Process - articole medicale engleza - startsanatate